Due to the role of STAT3 in tumorigenesis and the abnormal activation of the pathway in several cancer types (reviewed in [11], [18], and [19]) including GBM, the JAK2/STAT3 pathway has attracted considerable attention as a potential novel therapeutic target. This evidence concerns the gene JAK2 and cancer.